Researchers examined trends in adherence to various treatment among patients with psoriasis using data from a large health insurance database. For which therapy had the highest odds for adherence, read more.

News

News
Thursday, December 7, 2017
Medication nonadherence often disrupts the therapeutic benefit of psoriasis treatment. In a recent study, researchers evaluated potential barriers to treatment adherence in patients with psoriasis.
News
Monday, November 27, 2017
Researchers recently examined the link between bariatric surgery and risk for psoriasis among patients with obesity.
News
Monday, November 27, 2017
Researchers recently examined the risks for cancer in patients with psoriasis who are treated with tumor necrosis factor-α inhibitors.
News
Thursday, November 23, 2017
Researchers examined the risk of type 2 diabetes in patients with psoriasis.

NPF Endorsed Articles

NPF Endorsed Articles
Monday, December 15, 2014
Test Your Psoriasis Knowledge 1. A 66-year-old woman’s psoriasis suddenly worsened after she underwent a biopsy of a tumor in her breast.
NPF Endorsed Articles
Thursday, October 23, 2014
Thirteen early-career physicians receive National Psoriasis Foundation fellowships to study psoriasis.  
NPF Endorsed Articles
Friday, September 19, 2014
This article, based on a presentation that was given at the Interdisciplinary Autoimmune Summit held in June 2014 in Las Vegas, describes how to select the right biologic for a patient who has not previously received biologic therapy.   
NPF Endorsed Articles
Thursday, August 21, 2014
The interleukin-17A inhibitor secukinumab was effective in the treatment of psoriasis, according to 2 large studies. 

Research in Review

Research in Review
Wednesday, May 11, 2016
Make sure you do not mistake signs of psoriasis in patients of color.
Research in Review
Tuesday, April 19, 2016
Posters presented at The Winter Clinical Dermatology Conference-Hawaii look at treatment options for psoriasis.
Research in Review
Monday, March 28, 2016
Gary Goldenberg, MD, discusses the latest oral agents for individuals living with psoriasis.